Semaglutide

Summary

Semaglutide is a GLP-1 receptor agonist — a once-weekly injection (Ozempic, Wegovy) or daily pill (Rybelsus, and now an oral Wegovy) that mimics the gut hormone GLP-1 to lower blood sugar and sharply reduce appetite. It is the rare compound on this site backed by large, high-quality human trials and full FDA approval: it reliably produces major weight loss, improves type-2-diabetes control, and — in people with established heart disease — lowers the risk of heart attack, stroke, and cardiovascular death. The honest catch is not that the science is thin; it's that this strong evidence belongs to the regulated, prescribed drug used as it was studied. It does not automatically transfer to the compounded, imported, or "research-grade" semaglutide many people buy online, to off-label "microdosing," or to indefinite use without medical supervision — and the drug carries real side effects and a boxed warning. Weight also tends to return when the drug is stopped.

What people use it for

Semaglutide's approved uses are type 2 diabetes (Ozempic, Rybelsus), chronic weight management in adults with obesity or with overweight plus a weight-related condition (Wegovy), and — since 2024 — reducing cardiovascular risk in adults who have both established heart disease and overweight/obesity (Wegovy). Beyond those approved uses, it is widely sought off-label purely for weight loss and body composition, including by people who are not clinically obese, and there is a growing trend of "microdosing" (deliberately taking less than the prescribed dose) for appetite control or general "metabolic" goals. In biohacker and longevity circles it is sometimes framed as an anti-aging or healthspan tool. The evidence sections below describe what the trials actually tested versus what off-label and online use assumes.

Human evidence

This is the strongest human evidence base of any compound covered here, and it comes from large, randomized, placebo-controlled trials run for regulatory approval — not from a single clinic or research group.

Weight loss (the STEP program). In the pivotal STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), 1,961 adults with overweight or obesity but without diabetes received once-weekly semaglutide 2.4 mg or placebo, both with lifestyle support, for 68 weeks. The semaglutide group lost a mean of 14.9% of body weight versus 2.4% on placebo, and 86% of treated participants lost at least 5% of their weight — a magnitude of medical weight loss not previously seen outside surgery. Crucially, the weight loss depends on staying on the drug: in the STEP 4 trial (Rubino et al., JAMA, 2021), people who stopped semaglutide at week 20 and switched to placebo began regaining weight, while those who continued kept losing. The STEP 1 trial extension (Wilding et al., 2022) quantified this bluntly — roughly two-thirds of the lost weight was regained within a year of stopping. Semaglutide is therefore a long-term therapy for a chronic condition, not a short course that "fixes" weight permanently.

Type 2 diabetes and cardiovascular outcomes (SUSTAIN-6). In SUSTAIN-6 (Marso et al., NEJM, 2016), 3,297 adults with type 2 diabetes at high cardiovascular risk received semaglutide or placebo for 104 weeks. The primary composite of cardiovascular death, non-fatal heart attack, or non-fatal stroke occurred in 6.6% on semaglutide versus 8.9% on placebo — about a 26% relative reduction — driven mainly by fewer strokes. (This same trial also surfaced a safety signal for worsening diabetic retinopathy, covered under Safety.)

Cardiovascular outcomes without diabetes (SELECT). The landmark SELECT trial (Lincoff et al., NEJM, 2023) enrolled 17,604 adults who had established cardiovascular disease and overweight/obesity but not diabetes, and followed them for about 40 months on semaglutide 2.4 mg or placebo. Major adverse cardiovascular events fell by 20% (hazard ratio 0.80; 95% CI 0.72–0.90), alongside a mean weight reduction of roughly 9.4%. SELECT is what earned Wegovy its 2024 FDA cardiovascular indication, and it is notable because some of the cardiovascular benefit appeared earlier than weight loss alone would explain — suggesting effects beyond the number on the scale, though the mechanisms are still being studied.

Oral semaglutide. Oral semaglutide (Rybelsus) has been studied for diabetes since the PIONEER program, and in 2025 a higher-dose oral form for weight management was approved on the strength of the OASIS trials; in OASIS-4, oral semaglutide 25 mg produced about 16.6% mean weight loss when taken as directed — similar to the injection. This matters because it shows the molecule itself, not just the injectable format, carries the effect.

The fair summary: for weight loss, diabetes, and cardiovascular risk in the studied populations, semaglutide works, and the evidence is robust and independently scrutinized.

Animal / preclinical evidence

For most peptides on this site, animal data is the whole story; for semaglutide it is mostly of historical and mechanistic interest, because the human evidence above is what actually governs its use. The relevant preclinical points are about how it works and where the safety warnings come from. Semaglutide is an engineered analog of human GLP-1, structurally modified (including a fatty-acid chain that binds albumin) to resist breakdown and last about a week in the body. It activates GLP-1 receptors to increase insulin and suppress glucagon in a glucose-dependent way, slow gastric emptying, and act on appetite centers in the hypothalamus to reduce hunger and food intake — the mechanism behind both the blood-sugar and the weight effects. Separately, lifetime rodent studies found that semaglutide caused dose-dependent thyroid C-cell tumors in rats and mice; whether this translates to humans is unknown, but it is the basis for the drug's boxed warning (see Safety).

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Unlike most peptides here, semaglutide's headline effects are well documented in trials, so community reports of strong appetite suppression and rapid weight loss are consistent with the science. Where community experience departs from the evidence is in how the drug is being obtained and used: self-sourced compounded or "research" semaglutide, dosing by personal experimentation rather than a clinician's escalation schedule, "microdosing" for general wellness, and use by people the trials never enrolled (those who are not overweight, seeking cosmetic or longevity benefits). Reports from these off-label, off-protocol patterns cannot be read as evidence of safety or benefit, because the product quality, dose accuracy, and medical monitoring that the trials relied on are absent. Community reports of side effects (nausea, vomiting, fatigue, and occasionally severe GI events) are also common and align with the trial safety data.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

Semaglutide is a prescription medication whose dosing is individualized and supervised by a licensed clinician; the figures below describe what was administered in published trials, for context only. The trials used gradual dose escalation to limit gastrointestinal side effects rather than starting at the target dose. For weight management, STEP-program trials titrated once-weekly subcutaneous semaglutide up to 2.4 mg; for type 2 diabetes, SUSTAIN trials used 0.5 mg and 1.0 mg weekly (the approved Ozempic range was later extended to 2.0 mg). Oral semaglutide was studied at 7 mg and 14 mg daily for diabetes (Rybelsus) and 25 mg daily for weight management. These are trial doses of an FDA-approved, quality-controlled product taken under medical care — not a protocol to self-administer, and not transferable to compounded or gray-market product of unknown concentration.

Safety & side effects

Semaglutide's safety profile is well characterized from large trials and an FDA-approved label — a sharp contrast to the gray-market peptides on this site — but "well characterized" is not "risk-free."

Most common: gastrointestinal effects — nausea, vomiting, diarrhea, constipation, and abdominal pain — affecting a large share of users, usually most intense during dose escalation and often easing over time. These are the main reason people discontinue.

Labeled warnings: a boxed warning for thyroid C-cell tumors (based on the rodent data above), with the drug contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2; a clear human thyroid-cancer link has not been established but the warning stands. The label also warns about pancreatitis, gallbladder disease (gallstones, cholecystitis), acute kidney injury (typically from dehydration due to vomiting/diarrhea), hypoglycemia when combined with insulin or sulfonylureas, diabetic retinopathy complications (a signal seen in SUSTAIN-6 in people with diabetes), and gastrointestinal effects severe enough to matter for anesthesia — because semaglutide delays gastric emptying, anesthesiology groups have issued guidance on aspiration risk and holding the drug before surgery.

Emerging / unsettled: a 2024 single-center retrospective study (Hathaway et al., JAMA Ophthalmology) reported a higher rate of NAION — a rare eye condition that can cause sudden, usually permanent vision loss in one eye — among patients prescribed semaglutide. The signal is real enough that regulators have noted it (it has been added to product information in some regions as a very rare effect), but later studies have been mixed and causation is not established. Separately, concerns about suicidal thoughts were investigated by both the FDA and the EMA, and as of those reviews no causal link was found — an honest reading is "watched and not confirmed," not "proven safe forever." Finally, lean-muscle loss during rapid weight loss is a genuine discussion point: as with any large weight loss, some of the weight lost is muscle (up to roughly 40% of total in some analyses), though in trials like STEP 1 the overall ratio of muscle to fat still improved because fat loss dominated, and adequate protein plus resistance exercise is the commonly discussed mitigation. The long-term safety of taking semaglutide for many years, and of using it in people who are not obese, is still being established.

A separate, larger risk for this audience is the product itself. Everything above describes the FDA-approved drug. Compounded, imported, or "research-grade" semaglutide is a different risk picture entirely (see Regulatory status).

Regulatory / legal status

Semaglutide is FDA-approved — the key difference from every other peptide profiled here. It is approved as Ozempic (injection, type 2 diabetes; 2017), Rybelsus (oral, type 2 diabetes; 2019), and Wegovy (injection, chronic weight management; 2021), with Wegovy gaining a cardiovascular-risk-reduction indication in March 2024 and an oral Wegovy (semaglutide 25 mg) for weight management approved in 2025 and launched in the U.S. in January 2026. Used as prescribed, it is a legal, regulated medicine.

The complication is the gray and compounded market. During the 2022–2024 surge in demand, semaglutide was on the FDA drug-shortage list, which temporarily allowed compounding pharmacies to make their own versions; telehealth sites, med spas, and online vendors sold these widely, often far more cheaply than the brand drugs. The FDA declared the shortage resolved on February 21, 2025, after which large-scale compounding of "essentially a copy" of the approved drug is generally no longer permitted (with short wind-down windows for 503A and 503B facilities, and ongoing litigation). The FDA has repeatedly flagged concrete dangers in this market: dosing errors — patients unfamiliar with drawing up and injecting from vials have given themselves 5 to 20 times the intended dose — and the use of unapproved salt forms (semaglutide sodium, semaglutide acetate) that are different active ingredients from the approved drug and have not been shown safe or effective. As of late 2024 the FDA had logged hundreds of adverse-event reports tied to compounded semaglutide. Beyond compounding, semaglutide sold as a "research chemical" online is not an approved product for human use at all, and carries the same identity, purity, and dosing uncertainties as any unregulated peptide. Status and enforcement are evolving; this is not legal or medical advice.

In sport, GLP-1 receptor agonists are not currently on the WADA Prohibited List, but athletes should always check the current year's list directly.

Podcast / media mentions

Semaglutide is arguably the most-discussed drug of the decade — "Ozempic" has become shorthand for weight loss in mainstream media, comedy, fashion coverage, and countless health podcasts. The unusual thing about its media story is that, for once, the core claim is true: the drug really does produce large weight loss and cut cardiovascular events in rigorous trials. So the place to apply scrutiny is different from the other briefs on this site. Three gaps are worth listening for. First, the slide from "the approved drug works" to "so the compounded/online version is fine" — the FDA's documented dosing errors, unapproved salt forms, and adverse-event reports say otherwise. Second, the "microdosing" trend (popularized partly by celebrity disclosures) and cosmetic use in people who are not overweight — these are off-label patterns the trials did not test, so the strong evidence simply doesn't speak to them. Third, the framing of semaglutide as a permanent fix or a casual "biohack," which glosses over the boxed warning, the real side-effect burden, and the well-documented weight regain after stopping. As elsewhere, the useful critique is of the certainty and the framing — not of the people discussing a genuinely effective medicine, and not of the medicine itself, which has earned its approvals.